Information  X 
Enter a valid email address

ONCIMMUNE (ONC)

Related News

15-Feb-2021 07:54 AM

Oncimmune losses narrow as sales rise

Immunodiagnostics group Oncimmune posted a narrower first-half loss on the back of higher revenue and lower R&D spending. Pre-tax losses for the six months through November amounted to £2.8 million, compared to losses of £5.5 million year-on-
30-Oct-2020 02:29 PM

Oncimmune losses deepen on R&D, acquisition costs

Immunodiagnostics group Oncimmune posted a deeper first-half loss amid a rise in R&D and administrative expenses. Pre-tax losses for the six months through May amounted to £9.8 million, compared to losses of £8.5 million year-on-year. During
12-Feb-2020 08:50 AM

Oncimmune losses deepen on higher staff, R&D costs

Immunodiagnostics focused Oncimmune booked a deeper first-half loss on the back of higher staff and R&D costs. Pre-tax losses for the six months through November amounted to £5.9m, compared to losses of £3.8m on-year. Revenue rose to £
22-Nov-2019 09:30 AM

Broker Forecast - finnCap issues a broker note on Oncimmune Holdings Plc

finnCap today initiates coverage of Oncimmune Holdings Plc (LON:ONC) with a corporate investment rating and price target of 150p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
26-Jun-2019 09:03 AM

Oncimmune confident of profitable growth amid positive study results, distribution pacts

Immunodiagnostics group Oncimmune Holdings said it was confident of being able to generate 'material profitable revenues', thanks to several business developments. The company had earlier this month reported positive data from an early lung can
10-May-2019 07:50 AM

Oncimmune unveils plans for Chinese trial

Oncimmune, a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company, have announced the start of a multi-centre case control study
13-Feb-2019 08:26 AM

Oncimmune losses deepen on higher R&D and administrative spending

Immunodiagnostics system supplier Oncimmune Holdings said its annual losses deepened as it increased R&D spending. Pre-tax losses for the year through November amounted to £3.9m, compared to losses of £2.8m on-year. R&D spending rose to &pou
31-Oct-2018 08:41 AM

Oncimmune losses deepen, warns on revenue after partner talks collapse

Immunodiagnostics group Oncimmune Holdings posted a deeper annual loss and cut its revenue expectations for the current year due to the collapse of talks with a potential partner. Pre-tax losses for the year through May amounted to £6.3m, compared
04-Jun-2018 01:56 PM

Oncimmune expects annual operating costs, cash position to beat expectations

Cancer detection company Oncimmune Holdings said it expected its revenue for the year through March to be in line with market expectations, while its expectations for operating costs and its cash position were ahead of its expectations. 'With multip
04-Jun-2018 09:30 AM

Oncimmune sees revenue in line with expectations as 'good' progress continues

Early cancer detection company Oncimmune said Monday that new distribution agreements saw minimum sales commitments rise to £28.8m as the company continued to make 'good progress'. Since the release of interim results on 13 February, the
13-Feb-2018 03:20 PM

Broker Forecast - Bryan Garnier issues a broker note on Oncimmune Holdings Plc

Bryan Garnier today reaffirms its buy investment rating on Oncimmune Holdings Plc (LON:ONC) and raised its price target to 168p (from 154p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
13-Feb-2018 07:43 AM

Oncimmune reports H1 pretax loss as costs soar

Oncimmune reported a pretax loss to £2.8m for the six months to 30 November 2017, from a year-earlier loss of £2.5m while revenue for the period was just £77,000, down from £114,000. The wider pre-tax loss came as cost of sales so
19-Jan-2018 09:40 AM

Broker Forecast - Berenberg issues a broker note on Oncimmune Holdings Plc

Berenberg today initiates coverage of Oncimmune Holdings Plc (LON:ONC) with a buy investment rating and price target of 169p. Story provided by StockMarketWire.com...
21-Dec-2017 09:01 AM

Oncimmune validates EarlyCDT-Liver test

Oncimmune, an early cancer detection company, has validated its EarlyCDT-Liver test on schedule. A commercial test will be available on time from the first half of 2018. The EarlyCDT-Liver test is the second Oncimmune has developed based on its propriet
20-Oct-2017 07:15 AM

Oncimmune loss narrows

Oncimmune posted a narrower annual loss at it continues to develop and market its early cancer-detection technology. The company booked a net loss of £4.8m, narrowing from loss of £8.4m in the previous corresponding period that included finan
27-Sep-2017 02:18 PM

Oncimmune raises £5m via placing

Oncimmune Holdings has raised a total of approximately £5.0m (before expenses) by means of a conditional placing with new and existing investors of 4,166,667 Placing Shares at a price of 120p per share. Geoffrey-Hamilton Fairley, Oncimmune's C
19-Sep-2017 02:13 PM

Oncimmunce Holdings inks £500,000 distribution agreements

Oncimmunce Holdings, an early detection of cancer company, on Tuesday announced three distribution agreements worth £500,000. These agreements are for its EarlyCDT- Lung test with LabLab ApS, Diuvita Diagnostics AS and XboXLab AB in Denmark, Norwa
10-Feb-2017 07:48 AM

Oncimmune more than doubles H1 pretax loss

Oncimmune has more than doubled its H1 pretax loss to £2.5m, from a year-earlier loss of £1.1m. Revenue was just £114,000, from £272,000. Administrative and R&D expenses were a big part of the loss. "Oncimmune has continued t

a d v e r t i s e m e n t